Brain Ischemia Market Research Report Information by Condition Type (Focal Brain Ischemia and Global Brain Ischemia), Treatment [Angioplasty, Beta Blockers, Angiotensin-Converting Enzyme (ACE) Inhibitors and others], End User (Hospitals & Clinics, Research & Academic Institutes and others) and Region (the Americas, Europe, Asia-Pacific and the Middle East & Africa) - Global Forecast till 2032

Table of Contents

1. REPORT PROLOGUE

2. MARKET INTRODUCTION

2.1. Definition

2.2. Scope of the Study

2.2.1. Research Objective

2.2.2. Assumptions

2.2.3. Limitations

3. RESEARCH METHODOLOGY

3.1. Overview

3.2. Primary Research

3.3. Secondary Research

3.4. Market Size Estimation

4. MARKET DYNAMICS

4.1. Overview

4.2. Drivers

4.3. Restraints

4.4. Opportunities

5. MARKET FACTOR ANALYSIS

5.1. Porter’s Five Forces Analysis

5.1.1. Bargaining Power of Suppliers

5.1.2. Bargaining Power of Buyers

5.1.3. Threat of New Entrants

5.1.4. Threat of Substitutes

5.1.5. Intensity of Rivalry

5.2. Value Chain Analysis

6. GLOBAL BRAIN ISCHEMIA MARKET, BY CONDITION TYPE

6.1. Overview

6.2. Focal Brain Ischemia

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

6.3. Global Brain Ischemia

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7. GLOBAL BRAIN ISCHEMIA MARKET, BY TREATMENT

7.1. Overview

7.2. Angioplasty

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.3. Beta Blockers

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.4. Angiotensin-Converting Enzyme (ACE) Inhibitors

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.5. Others

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

8. GLOBAL BRAIN ISCHEMIA MARKET, BY END USER

8.1. Overview

8.2. Hospitals & Clinics

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

8.3. Research and Academic Institutes

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

8.4. Others

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

9. GLOBAL BRAIN ISCHEMIA MARKET, BY REGION

9.1. Overview

9.2. Americas

9.2.1. North America

9.2.1.1. US

9.2.1.2. Canada

9.2.2. Latin America

9.3. Europe

9.3.1. Western Europe

9.3.1.1. Germany

9.3.1.2. France

9.3.1.3. Italy

9.3.1.4. Spain

9.3.1.5. UK

9.3.1.6. Rest of Western Europe

9.3.2. Eastern Europe

9.4. Asia-Pacific

9.4.1. Japan

9.4.2. China

9.4.3. India

9.4.4. Australia

9.4.5. South Korea

9.4.6. Rest of Asia-Pacific

9.5. Middle East & Africa

9.5.1. Middle East

9.5.2. Africa

10. COMPANY LANDSCAPE

10.1. Overview

10.2. Competitive Analysis

10.3. Market Share Analysis

10.4. Major Growth Strategy in the Global Brain Ischemia Market

10.5. Competitive Benchmarking

10.6. Leading Players in terms of Number of Developments in the Global Brain Ischemia Market

10.7. Key Developments and Growth Strategies

10.7.1. New Product Launch/Service Deployment

10.7.2. Mergers and Acquisitions

10.7.3. Joint Ventures

10.8. Major Players Financial Matrix & Market Ratio

10.8.1. Sales & Operating Income 2020

10.8.2. Major Players R&D Expenditure 2020

10.9. Major Players Capital Market Ratio

11. COMPANY PROFILES

11.1. Taxus Cardium

11.1.1. Company Overview

11.1.2. Product Overview

11.1.3. Financial Overview

11.1.4. Key Developments

11.1.5. SWOT Analysis

11.1.6. Key Strategies

11.2. Edwards Lifesciences Corporation

11.2.1. Company Overview

11.2.2. Product Overview

11.2.3. Financial Overview

11.2.4. Key Developments

11.2.5. SWOT Analysis

11.2.6. Key Strategies

11.3. Boston Scientific Corporation

11.3.1. Company Overview

11.3.2. Product Overview

11.3.3. Financial Overview

11.3.4. Key Developments

11.3.5. SWOT Analysis

11.3.6. Key Strategies

11.4. Merck KGaA

11.4.1. Company Overview

11.4.2. Product Overview

11.4.3. Financial Overview

11.4.4. Key Developments

11.4.5. SWOT Analysis

11.4.6. Key Strategies

11.5. Medtronic

11.5.1. Company Overview

11.5.2. Product Overview

11.5.3. Financial Overview

11.5.4. Key Developments

11.5.5. SWOT Analysis

11.5.6. Key Strategies

11.6. Cook Medical

11.6.1. Company Overview

11.6.2. Product Overview

11.6.3. Financial Overview

11.6.4. Key Developments

11.6.5. SWOT Analysis

11.6.6. Key Strategies

11.7. Novartis AG

11.7.1. Company Overview

11.7.2. Product Overview

11.7.3. Financial Overview

11.7.4. Key Developments

11.7.5. SWOT Analysis

11.7.6. Key Strategies

11.8. Boehringer Ingelheim International GmbH

11.8.1. Company Overview

11.8.2. Product Overview

11.8.3. Financial Overview

11.8.4. Key Developments

11.8.5. SWOT Analysis

11.8.6. Key Strategies

11.9. Abbott

11.9.1. Company Overview

11.9.2. Product Overview

11.9.3. Financial Overview

11.9.4. Key Developments

11.9.5. SWOT Analysis

11.9.6. Key Strategies

11.10. Becton, Dickinson and Company

11.10.1. Company Overview

11.10.2. Product Overview

11.10.3. Financial Overview

11.10.4. Key Developments

11.10.5. SWOT Analysis

11.10.6. Key Strategies

11.11. Johnson & Johnson Services, Inc.

11.11.1. Company Overview

11.11.2. Product Overview

11.11.3. Financial Overview

11.11.4. Key Developments

11.11.5. SWOT Analysis

11.11.6. Key Strategies

11.12. Bayer AG

11.12.1. Company Overview

11.12.2. Product Overview

11.12.3. Financial Overview

11.12.4. Key Developments

11.12.5. SWOT Analysis

11.12.6. Key Strategies

11.13. AstraZeneca

11.13.1. Company Overview

11.13.2. Product Overview

11.13.3. Financial Overview

11.13.4. Key Developments

11.13.5. SWOT Analysis

11.13.6. Key Strategies

11.14. Others

12. APPENDIX

12.1. References

12.2. Related Reports

LIST OF TABLES

TABLE 1 GLOBAL BRAIN ISCHEMIA MARKET SYNOPSIS, 2020-2027

TABLE 2 GLOBAL BRAIN ISCHEMIA MARKET ESTIMATES & FORECAST, 2020-2027 (USD MILLION)

TABLE 3 GLOBAL BRAIN ISCHEMIA MARKET, BY CONDITION TYPE, 2020-2027 (USD MILLION)

TABLE 4 GLOBAL BRAIN ISCHEMIA MARKET, BY TREATMENT, 2020-2027 (USD MILLION)

TABLE 5 GLOBAL BRAIN ISCHEMIA MARKET, BY END USER, 2020-2027 (USD MILLION)

TABLE 6 GLOBAL BRAIN ISCHEMIA MARKET, BY REGION, 2020-2027 (USD MILLION)

TABLE 7 NORTH AMERICA: BRAIN ISCHEMIA MARKET, BY CONDITION TYPE, 2020-2027 (USD MILLION)

TABLE 8 NORTH AMERICA: BRAIN ISCHEMIA MARKET, BY TREATMENT, 2020-2027 (USD MILLION)

TABLE 9 NORTH AMERICA: BRAIN ISCHEMIA MARKET, BY END USER, 2020-2027 (USD MILLION)

TABLE 10 US: BRAIN ISCHEMIA MARKET, BY CONDITION TYPE, 2020-2027 (USD MILLION)

TABLE 11 US: BRAIN ISCHEMIA MARKET, BY TREATMENT, 2020-2027 (USD MILLION)

TABLE 12 US: BRAIN ISCHEMIA MARKET, BY END USER, 2020-2027 (USD MILLION)

TABLE 13 CANADA: BRAIN ISCHEMIA MARKET, BY CONDITION TYPE, 2020-2027 (USD MILLION)

TABLE 14 CANADA: BRAIN ISCHEMIA MARKET, BY TREATMENT, 2020-2027 (USD MILLION)

TABLE 15 CANADA: BRAIN ISCHEMIA MARKET, BY END USER, 2020-2027 (USD MILLION)

TABLE 16 LATIN AMERICA: BRAIN ISCHEMIA MARKET, BY CONDITION TYPE, 2020-2027 (USD MILLION)

TABLE 17 LATIN AMERICA: BRAIN ISCHEMIA MARKET, BY TREATMENT, 2020-2027 (USD MILLION)

TABLE 18 LATIN AMERICA: BRAIN ISCHEMIA MARKET, BY END USER, 2020-2027 (USD MILLION)

TABLE 19 EUROPE: BRAIN ISCHEMIA MARKET, BY CONDITION TYPE, 2020-2027 (USD MILLION)

TABLE 20 EUROPE: BRAIN ISCHEMIA MARKET, BY TREATMENT, 2020-2027 (USD MILLION)

TABLE 21 EUROPE: BRAIN ISCHEMIA MARKET, BY END USER, 2020-2027 (USD MILLION)

TABLE 22 WESTERN EUROPE: BRAIN ISCHEMIA MARKET, BY CONDITION TYPE, 2020-2027 (USD MILLION)

TABLE 23 WESTERN EUROPE: BRAIN ISCHEMIA MARKET, BY TREATMENT, 2020-2027 (USD MILLION)

TABLE 24 WESTERN EUROPE: BRAIN ISCHEMIA MARKET, BY END USER, 2020-2027 (USD MILLION)

TABLE 25 EASTERN EUROPE: BRAIN ISCHEMIA MARKET, BY CONDITION TYPE, 2020-2027 (USD MILLION)

TABLE 26 EASTERN EUROPE: BRAIN ISCHEMIA MARKET, BY TREATMENT, 2020-2027 (USD MILLION)

TABLE 27 EASTERN EUROPE: BRAIN ISCHEMIA MARKET, BY END USER, 2020-2027 (USD MILLION)

TABLE 28 ASIA-PACIFIC: BRAIN ISCHEMIA MARKET, BY CONDITION TYPE, 2020-2027 (USD MILLION)

TABLE 29 ASIA-PACIFIC: BRAIN ISCHEMIA MARKET, BY TREATMENT, 2020-2027 (USD MILLION)

TABLE 30 ASIA-PACIFIC: BRAIN ISCHEMIA MARKET, BY END USER, 2020-2027 (USD MILLION)

TABLE 31 MIDDLE EAST & AFRICA: BRAIN ISCHEMIA MARKET, BY CONDITION TYPE, 2020-2027 (USD MILLION)

TABLE 32 MIDDLE EAST & AFRICA: BRAIN ISCHEMIA MARKET, BY TREATMENT, 2020-2027 (USD MILLION)

TABLE 33 MIDDLE EAST & AFRICA: BRAIN ISCHEMIA MARKET, BY END USER, 2020-2027 (USD MILLION)

LIST OF FIGURES

FIGURE 1 RESEARCH PROCESS

FIGURE 2 MARKET STRUCTURE OF THE GLOBAL BRAIN ISCHEMIA MARKET

FIGURE 3 MARKET DYNAMICS OF THE GLOBAL BRAIN ISCHEMIA MARKET

FIGURE 4 GLOBAL BRAIN ISCHEMIA MARKET SHARE, BY CONDITION TYPE, 2020 (%)

FIGURE 5 GLOBAL BRAIN ISCHEMIA MARKET SHARE, BY TREATMENT, 2020 (%)

FIGURE 6 GLOBAL BRAIN ISCHEMIA MARKET SHARE, BY END USER, 2020 (%)

FIGURE 7 GLOBAL BRAIN ISCHEMIA MARKET SHARE, BY REGION, 2020 (%)

FIGURE 7 AMERICAS: BRAIN ISCHEMIA MARKET SHARE BY REGION, 2020 (%)

FIGURE 8 NORTH AMERICA: BRAIN ISCHEMIA MARKET SHARE, BY COUNTRY, 2020 (%)

FIGURE 9 EUROPE: BRAIN ISCHEMIA MARKET SHARE, BY REGION, 2020 (%)

FIGURE 10 WESTERN EUROPE: BRAIN ISCHEMIA MARKET SHARE, BY COUNTRY, 2020 (%)

FIGURE 11 ASIA-PACIFIC: BRAIN ISCHEMIA MARKET SHARE, BY COUNTRY, 2020 (%)

FIGURE 12 MIDDLE EAST & AFRICA: BRAIN ISCHEMIA MARKET SHARE, BY COUNTRY, 2020 (%)

FIGURE 13 GLOBAL BRAIN ISCHEMIA MARKET: COMPANY SHARE ANALYSIS, 2020 (%)

FIGURE 14 TAXUS CARDIUM.: KEY FINANCIALS

FIGURE 15 TAXUS CARDIUM: SEGMENTAL REVENUE

FIGURE 16 TAXUS CARDIUM: REGIONAL REVENUE

FIGURE 17 EDWARDS LIFESCIENCES CORPORATION: KEY FINANCIALS

FIGURE 18 EDWARDS LIFESCIENCES CORPORATION: SEGMENTAL REVENUE

FIGURE 19 EDWARDS LIFESCIENCES CORPORATION: REGIONAL REVENUE

FIGURE 20 BOSTON SCIENTIFIC CORPORATION: KEY FINANCIALS

FIGURE 21 BOSTON SCIENTIFIC CORPORATION: SEGMENTAL REVENUE

FIGURE 22 BOSTON SCIENTIFIC CORPORATION: REGIONAL REVENUE

FIGURE 23 MERCK KGAA: KEY FINANCIALS

FIGURE 24 MERCK KGAA: SEGMENTAL REVENUE

FIGURE 25 MERCK KGAA: REGIONAL REVENUE

FIGURE 26 MEDTRONIC: KEY FINANCIALS

FIGURE 27 MEDTRONIC: SEGMENTAL REVENUE

FIGURE 28 MEDTRONIC: REGIONAL REVENUE

FIGURE 29 COOK MEDICAL: KEY FINANCIALS

FIGURE 30 COOK MEDICAL: SEGMENTAL REVENUE

FIGURE 31 COOK MEDICAL: REGIONAL REVENUE

FIGURE 32 NOVARTIS AG: KEY FINANCIALS

FIGURE 33 NOVARTIS AG: SEGMENTAL REVENUE

FIGURE 34 NOVARTIS AG: REGIONAL REVENUE

FIGURE 35 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: KEY FINANCIALS

FIGURE 36 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: SEGMENTAL REVENUE

FIGURE 37 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: REGIONAL REVENUE

FIGURE 38 ABBOTT: KEY FINANCIALS

FIGURE 39 ABBOTT: SEGMENTAL REVENUE

FIGURE 40 ABBOTT: REGIONAL REVENUE

FIGURE 41 BECTON, DICKINSON AND COMPANY: KEY FINANCIALS

FIGURE 42 BECTON, DICKINSON AND COMPANY: SEGMENTAL REVENUE

FIGURE 43 BECTON, DICKINSON AND COMPANY: REGIONAL REVENUE

FIGURE 44 JOHNSON & JOHNSON SERVICES, INC.: KEY FINANCIALS

FIGURE 45 JOHNSON & JOHNSON SERVICES, INC.: SEGMENTAL REVENUE

FIGURE 46 JOHNSON & JOHNSON SERVICES, INC.: REGIONAL REVENUE

FIGURE 47 BAYER AG: KEY FINANCIALS

FIGURE 48 BAYER AG: SEGMENTAL REVENUE

FIGURE 49 BAYER AG: REGIONAL REVENUE

FIGURE 50 ASTRAZENECA: KEY FINANCIALS

FIGURE 51 ASTRAZENECA: SEGMENTAL REVENUE

FIGURE 52 ASTRAZENECA: REGIONAL REVENUE